Is ORMP or OVID more undervalued in 2026?

CirclFi compares Oramed Pharmaceuticals Inc. (ORMP) and Ovid Therapeutics Inc. (OVID) using 13 institutional-grade valuation models. ORMP has a Quality of Company score of 7.1/10 while OVID scores 5.3/10.

Which is a better buy — ORMP or OVID?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ORMP and OVID valuations compare?

ORMP at $3.97 and OVID at $2.73 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ORMP vs OVID Valuation Comparison 2026 — Intrinsic Value Analysis

ORMP

Pharmaceutical Preparations

Oramed Pharmaceuticals Inc.

Quality

7.1

out of 10

Value Trap

SAFE

Price

$3.97

Last close

Models

9/13

Active

OVID

Pharmaceutical Preparations

Ovid Therapeutics Inc.

Quality

5.3

out of 10

Value Trap

LOW

Price

$2.73

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	ORMP Fair Value	ORMP Upside	OVID Fair Value	OVID Upside
Bayesian DCF	Intrinsic	$8.79	+121.3%	$0.75	-72.6%
Earnings Power Value	Intrinsic	$11.49	+188.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.15	-70.9%	$0.83	-69.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ORMP vs OVID — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ORMP vs OVID — Which Stock Is More Undervalued?

ORMP scores higher with a 7.1/10 quality rating vs OVID's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oramed Pharmaceuticals Inc. (ORMP) and Ovid Therapeutics Inc. (OVID) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ORMP currently trades at $3.97 with a QOC of 7.1/10, while OVID trades at $2.73 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).